超33亿美元！默沙东接近完成一笔新收购

Core Insights - Merck is nearing an agreement to acquire biotech company Cidara Therapeutics, with the deal likely valuing Cidara above its current market cap of $3.3 billion, potentially announced as early as this Friday [1] - The acquisition is driven by Cidara's promising drug CD388, which recently received "Breakthrough Therapy" designation from the FDA, highlighting its clinical value in preventing influenza in high-risk populations [2] Company Summary - Merck is competing with another pharmaceutical company for the acquisition of Cidara, with the final decision favoring Merck's proposal [1] - The specific price of the acquisition has not been disclosed, but it is expected to involve a combination of cash and milestone payments linked to clinical trial achievements of Cidara's drugs [1] - Cidara has not commented on the acquisition rumors, and Merck has not responded to inquiries regarding the matter [1] Industry Summary - The "Breakthrough Therapy" designation by the FDA is designed to expedite the development and review of drugs for serious diseases or unmet medical needs, underscoring the significance of CD388 in the influenza prevention market [2] - If the acquisition is successful, it will enhance Merck's pipeline in the anti-infective space, while Cidara's innovative drug development capabilities will benefit from Merck's resources, potentially leading to faster market introduction of new treatment options for influenza prevention [2]